The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Comprehensive Functional Annotation of Human CPS1 (Carbamoyl-Phosphate Synthase 1, Mitochondrial)

Gene and Protein Identity

CPS1 (gene symbol: CPS1; UniProt accession: P31327; ENSG00000021826) encodes carbamoyl-phosphate synthase [ammonia], mitochondrial (also known as carbamoyl-phosphate synthetase I, CPSase I; EC 6.3.4.16). The gene is located on human chromosome 2q35 and comprises 38 exons (dong2024clinicalfeaturesand pages 5-6). The CPS1 protein is synthesized as a 1,500-amino acid precursor, with an N-terminal mitochondrial targeting sequence of approximately 38 residues that is cleaved upon import into the mitochondrial matrix, yielding a mature enzyme of 1,462 residues (~160 kDa) (fernandez2015usingrecombinanthuman pages 71-77, fernandez2015usingrecombinanthuman pages 106-110, fernandez2015usingrecombinanthuman pages 85-89). CPS1 is expressed exclusively in hepatocytes and enterocytes (liver and small intestine), where it constitutes an extraordinarily abundant enzyme, comprising 10–25% of the total mitochondrial matrix protein in liver (pekkala2010understandingcarbamoyl‐phosphatesynthetase pages 1-2, fernandez2015usingrecombinanthuman pages 37-41).

The summary table below provides a quick-reference overview of CPS1's key properties:

Table: This table summarizes the verified identity, biochemical function, regulation, localization, disease relevance, and structural resources for human CPS1 (UniProt P31327). It is useful as a compact reference for the main facts needed in a functional-annotation report.

Enzymatic Reaction and Catalytic Mechanism

CPS1 catalyzes the first and rate-limiting step of the urea cycle: the ATP-dependent synthesis of carbamoyl phosphate from ammonia, bicarbonate, and two molecules of ATP (fernandez2015usingrecombinanthuman pages 71-77, yao2020smallmoleculeinhibition pages 1-3). The overall reaction is:

2 ATP + NH₃ + HCO₃⁻ → carbamoyl phosphate + 2 ADP + Pᵢ

This reaction proceeds through a three-step catalytic mechanism involving two unstable intermediates (fernandez2015usingrecombinanthuman pages 37-41, fernandez2015usingrecombinanthuman pages 41-44):

1. Bicarbonate phosphorylation: The first ATP molecule phosphorylates bicarbonate at the N-terminal phosphorylation domain, forming the highly reactive intermediate carboxyphosphate (also referred to as "active CO₂").
2. Carbamate formation: Ammonia reacts with carboxyphosphate to form carbamate, releasing inorganic phosphate.
3. Carbamate phosphorylation: The second ATP molecule phosphorylates carbamate at the C-terminal phosphorylation domain, producing the final product, carbamoyl phosphate.

The two reactive intermediates (carboxyphosphate and carbamate) are shielded from water as they migrate between the two phosphorylation centers through an intraenzymatic pathway (fernandez2015usingrecombinanthuman pages 41-44). An important kinetic feature is that the intraenzymatic reversible reaction between ATP and bicarbonate occurs much faster than the overall reaction, representing a rapid equilibrium step followed by slower ammonia incorporation (fernandez2015usingrecombinanthuman pages 37-41).

A critical distinction from CPS2 (the cytosolic carbamoyl phosphate synthetase II, part of the CAD multienzymatic complex involved in pyrimidine biosynthesis) is that CPS1 uses free ammonia directly as its nitrogen source, rather than glutamine (fernandez2015usingrecombinanthuman pages 24-31). CPS1 possesses an approximately 100-fold higher affinity for ammonia compared to bacterial CPS, making it well-suited for detoxification of ammonia at portal blood concentrations (fernandez2015usingrecombinanthuman pages 37-41).

Domain Architecture and Structural Biology

CPS1 is a multidomain enzyme organized as a single polypeptide chain with fused subunit domains that can be functionally divided into a small subunit region (~40 kDa) and a large subunit region (~120 kDa) (fernandez2015usingrecombinanthuman pages 106-110, fernandez2015usingrecombinanthuman pages 41-44). The large subunit region functions as a pseudohomodimer, containing two homologous ~60 kDa halves, each consisting of an ~45 kDa phosphorylation domain followed by an ~15 kDa domain:

• N-terminal phosphorylation domain: Catalyzes bicarbonate phosphorylation (the "ATP A" domain).
• C-terminal phosphorylation domain: Catalyzes carbamate phosphorylation (the "ATP B" domain).
• Integrating domain (UFSD): A ~17.7 kDa subdomain (residues 822–973) connecting the two phosphorylation domains; it has no substrate sites or catalytic components but contains an allosteric pocket exploited by small-molecule inhibitors (fernandez2015usingrecombinanthuman pages 106-110, yao2020smallmoleculeinhibition pages 5-7).
• Allosteric/regulatory domain (ASD): The C-terminal ~20 kDa domain (residues 1354–1500) binds the essential allosteric activator N-acetyl-L-glutamate (NAG) and controls the enzyme's on/off state (fernandez2015usingrecombinanthuman pages 106-110, fernandez2015usingrecombinanthuman pages 133-137).

The crystal structure of human CPS1 has been determined, with key depositions in the Protein Data Bank including PDB 5DOT (apo form), 5DOU (liganded form), and 6UEL (CPS1 in complex with the allosteric inhibitor H3B-193, resolved at 1.90 Å) (yao2020smallmoleculeinhibition pages 5-7, yao2020smallmoleculeinhibition pages 14-15). The co-crystal structure of CPS1 with H3B-193 revealed a previously unknown allosteric pocket located between the integrating and ATP A domains, approximately 10 Å wide at its opening and 24 Å deep, lined with hydrophobic residues (M656, V664, F809, L813, I851). Binding of the inhibitor induces a conformational change in the flexible K-loop (residues V653–H659), which flips out of the ATP binding pocket to stabilize the inhibitor (yao2020smallmoleculeinhibition pages 5-7).

Subcellular Localization and Supramolecular Organization

CPS1 resides in the mitochondrial matrix after cleavage of its N-terminal targeting peptide (fernandez2015usingrecombinanthuman pages 85-89, fernandez2015usingrecombinanthuman pages 37-41). Elegant studies using super-resolution gated stimulation emission depletion (gSTED) microscopy and biochemical fractionation have demonstrated that CPS1, together with N-acetylglutamate synthase (NAGS) and ornithine transcarbamylase (OTC), forms dynamic nanoclusters at the inner mitochondrial membrane (IMM) rather than functioning as isolated soluble matrix enzymes (haskins2021mitochondrialenzymesof pages 2-3, haskins2021mitochondrialenzymesof pages 1-2, haskins2021mitochondrialenzymesof pages 11-13). Approximately 35% of CPS1 and 30% of OTC partition with the IMM fraction, and these proteins co-immunoprecipitate (haskins2021mitochondrialenzymesof pages 11-13). The clusters measure 100–150 nm and contain multiple urea cycle enzymes, facilitating efficient channeling of the unstable intermediate carbamoyl phosphate and potentially increasing pathway flux up to 100-fold through increased local enzyme and metabolite concentrations (haskins2021mitochondrialenzymesof pages 13-14). The mammalian-specific "variable segment" of NAGS mediates the interaction between NAGS and CPS1 within these clusters (haskins2021mitochondrialenzymesof pages 1-2). Surface amino acid mutations in CPS1 and OTC that do not affect catalytic activity or protein stability can nonetheless impair ureagenesis by disrupting these enzyme–enzyme interactions, underscoring the functional importance of the supramolecular organization (haskins2021mitochondrialenzymesof pages 5-7, haskins2021mitochondrialenzymesof pages 7-10).

Metabolic Pathway Context

The Urea Cycle

CPS1 catalyzes the first committed step of the urea cycle, which consists of five enzymatic reactions: CPS1 → OTC → argininosuccinate synthetase (ASS1) → argininosuccinate lyase (ASL) → arginase (ARG1) (mitchell2009geneticvariationin pages 2-3, yao2020smallmoleculeinhibition pages 1-3). The carbamoyl phosphate produced by CPS1 is immediately transferred to OTC, which combines it with ornithine to form citrulline—the first specific intermediate of the urea cycle (fernandez2015usingrecombinanthuman pages 37-41, haskins2021mitochondrialenzymesof pages 2-3). The urea cycle is the only mammalian pathway capable of efficiently converting ammonia into urea, sufficient to detoxify tens of grams of ammonia daily (zhu2026ureacycledysregulation pages 5-7). In the liver, the urea cycle operates as a high-capacity system for ammonia removal in periportal hepatocytes, complementing the high-affinity glutamine synthetase system in perivenous hepatocytes (fernandez2015usingrecombinanthuman pages 37-41).

Connection to Pyrimidine Biosynthesis

Beyond the urea cycle, carbamoyl phosphate produced by CPS1 can leak from mitochondria to the cytosol, where it serves as a substrate for pyrimidine biosynthesis via the cytosolic CAD enzyme complex (CPS2/ATCase/DHOase). This alternative metabolic fate is particularly significant in cancer cells with high CPS1 expression, where increased carbamoyl phosphate production fuels nucleotide synthesis to support rapid proliferation (hajaj2023fromtheinside pages 4-5).

Regulation of CPS1 Activity

Allosteric Activation by N-Acetylglutamate (NAG)

CPS1 is essentially inactive without its obligate allosteric activator, N-acetyl-L-glutamate (NAG), which is synthesized by NAGS from acetyl-CoA and glutamate (nakagawa2009sirt5deacetylatescarbamoyl pages 3-4, pekkala2010understandingcarbamoyl‐phosphatesynthetase pages 1-2). NAG binds to the C-terminal allosteric domain and is required for the enzyme to adopt a catalytically competent conformation. This allosteric regulation provides the primary on/off switch for flux through the urea cycle (fernandez2015usingrecombinanthuman pages 133-137).

Post-Translational Regulation by SIRT5

The mitochondrial sirtuin SIRT5, an NAD⁺-dependent deacetylase localized to the mitochondrial matrix, was identified as a specific regulator of CPS1 (nakagawa2009sirt5deacetylatescarbamoyl pages 1-2, nakagawa2009sirt5deacetylatescarbamoyl pages 3-4). SIRT5 deacetylates CPS1, increasing its enzymatic activity. During fasting and calorie restriction, mitochondrial NAD⁺ levels rise approximately two-fold, upregulating SIRT5 activity and thereby promoting CPS1 deacetylation and ammonia disposal (nakagawa2009sirt5deacetylatescarbamoyl pages 5-6, nakagawa2009sirt5deacetylatescarbamoyl pages 6-7). SIRT5 knockout mice exhibit significantly elevated blood ammonia levels following fasting, demonstrating the physiological importance of this regulatory mechanism (nakagawa2009sirt5deacetylatescarbamoyl pages 6-7). This regulation is specific to SIRT5, as other mitochondrial sirtuins (SIRT3, SIRT4) do not affect CPS1 activity (nakagawa2009sirt5deacetylatescarbamoyl pages 3-4).

Post-Translational Regulation by O-GlcNAcylation

O-linked N-acetylglucosamine glycosylation (O-GlcNAcylation) represents another layer of nutrient-responsive CPS1 regulation. Two studies have provided complementary but mechanistically distinct findings:

• Soria et al. (2022, Nature Communications) demonstrated that O-GlcNAcylation at specific threonine residues (Thr109, Thr110, and Thr1078) enhances CPS1 catalytic efficiency for ammonia and promotes ureagenesis. Pharmacological inhibition of O-GlcNAcase (OGA) with Thiamet-G increased CPS1 O-GlcNAcylation and reduced hyperammonemia in mouse models of both genetic (propionic acidemia) and acquired (thioacetamide-induced liver failure) liver diseases (soria2022oglcnacylationenhancescps1 pages 4-4, soria2022oglcnacylationenhancescps1 pages 6-7, soria2022oglcnacylationenhancescps1 pages 7-8).

• Wu et al. (2022, Journal of Molecular Cell Biology) found that global O-GlcNAc levels increase in aged tissues, with CPS1 being among the most heavily O-GlcNAcylated proteins in aged liver. In their model, high glucose stimulates CPS1 O-GlcNAcylation and inhibits CPS1 activity, while calorie restriction reverses CPS1 O-GlcNAcylation. The O-GlcNAcylation site Ser537 was identified as important for regulation (wu2022regulationofthe pages 1-2, wu2022regulationofthe pages 2-5, wu2022regulationofthe pages 5-6).

These findings collectively position CPS1 O-GlcNAcylation as a nutrient-sensing mechanism linking dietary status and aging to urea cycle regulation, though the opposing functional effects reported may reflect context-dependent or site-specific modifications (wu2022regulationofthe pages 7-9).

Additional Post-Translational Modifications

Beyond acetylation and O-GlcNAcylation, CPS1 has been found to undergo malonylation, succinylation, fatty acylation, and nitration, which generally have neutral or negative effects on enzyme activity (soria2022oglcnacylationenhancescps1 pages 6-7). Phosphorylation sites on CPS1, including pY590, pY852, and pY1450, have been mapped to binding domains for NAG, substrates, and dimer interfaces, suggesting additional regulatory inputs (evidence from phosphoproteomic studies).

Disease Associations

CPS1 Deficiency (OMIM 237300)

CPS1 deficiency (CPS1D) is a rare autosomal recessive inborn error of the urea cycle characterized by severe hyperammonemia (dong2024clinicalfeaturesand pages 1-2, pekkala2010understandingcarbamoyl‐phosphatesynthetase pages 1-2). The disease presents in two clinical forms:

• Early-onset (neonatal): Manifests within the first days of life with poor feeding, vomiting, lethargy, seizures, and rapidly progressive encephalopathy. Without treatment, neonatal-onset CPS1D is typically lethal (dong2024clinicalfeaturesand pages 4-5, dong2024clinicalfeaturesand pages 1-2).
• Late-onset: Presents from childhood to adulthood with variable severity, including developmental delay, psychiatric symptoms, and metabolic crises triggered by high-protein intake or acute illness (dong2024clinicalfeaturesand pages 4-5, wang2023clinicalandgenetic pages 3-5).

In a 2024 cohort of seven Chinese patients, peak blood ammonia levels ranged from 160 to 1,000 µmol/L, with low citrulline and arginine levels being characteristic biochemical findings. Four of seven patients died, and 10 of 12 identified CPS1 variants were novel, highlighting the broad mutation spectrum without hotspot variants (dong2024clinicalfeaturesand pages 4-5, dong2024clinicalfeaturesand pages 5-6). Treatment modalities include ammonia scavengers (sodium phenylbutyrate, sodium benzoate), arginine supplementation, low-protein diet, hemodialysis during acute crises, and liver transplantation as definitive therapy (dong2024clinicalfeaturesand pages 4-5, wang2023clinicalandgenetic pages 3-5). Some patients may respond to N-carbamyl-L-glutamate (NCG), a stable NAG analog that can activate residual CPS1 enzyme activity (fernandez2015usingrecombinanthuman pages 133-137).

CPS1 is also associated with hyperammonemia, kidney failure, venous thromboembolism, and skeletal abnormalities through genetic association studies (OpenTargets Search: -CPS1).

CPS1 in Cancer

CPS1 exhibits a paradoxical dual role in cancer. In hepatocellular carcinoma (HCC), CPS1 expression is frequently suppressed through DNA methylation of CpG dinucleotides near the transcription start site. In 80.6% of 36 HCC tumor samples examined, CPS1 mRNA levels were significantly lower than in noncancerous tissue (liu2011dnamethylationsuppresses pages 4-6). In non-alcoholic fatty liver disease (NAFLD/NASH), CPS1 mRNA levels are decreased by 30–40% on average, contributing to impaired urea production and hyperammonemia (zhu2026ureacycledysregulation pages 5-7).

Conversely, CPS1 is upregulated in multiple extrahepatic cancers including rectal, stomach, melanoma, sarcoma, lung carcinoma, glioma, glioblastoma, and B-cell lymphoma (hajaj2023fromtheinside pages 4-5). In these contexts, elevated CPS1 activity increases carbamoyl phosphate production, which leaks from mitochondria to the cytosol and serves as substrate for pyrimidine biosynthesis, supporting tumor cell proliferation. Silencing CPS1 in such cancer cells results in cell death through pyrimidine depletion both in vitro and in vivo (hajaj2023fromtheinside pages 4-5). The first small-molecule CPS1 inhibitor, H3B-120 (IC₅₀ ~1.5 µM), was identified through high-throughput screening and demonstrated cellular activity in blocking both urea cycle function and pyrimidine biosynthesis support in primary human hepatocytes, establishing CPS1 as a druggable oncology target (yao2020smallmoleculeinhibition pages 4-5, yao2020smallmoleculeinhibition pages 1-3).

Conclusions

CPS1 is a highly abundant mitochondrial matrix enzyme that catalyzes the first and rate-limiting reaction of the urea cycle, converting ammonia, bicarbonate, and two ATP molecules into carbamoyl phosphate through a three-step mechanism involving carboxyphosphate and carbamate intermediates. The enzyme absolutely requires N-acetylglutamate as an allosteric activator and is further regulated by multiple post-translational modifications including SIRT5-mediated deacetylation and O-GlcNAcylation, which link its activity to nutritional status and aging. CPS1, together with NAGS and OTC, forms dynamic nanoclusters at the inner mitochondrial membrane that facilitate efficient substrate channeling. Deficiency of CPS1 causes severe hyperammonemia with high morbidity and mortality, while its aberrant expression in cancer—either suppressed in HCC or upregulated in extrahepatic tumors—contributes to metabolic reprogramming. The availability of high-resolution crystal structures and the identification of druggable allosteric pockets position CPS1 as an active area of both basic and translational research.

References

1. (dong2024clinicalfeaturesand pages 5-6): Hui Dong, Tian Sang, Xue Ma, Jinqing Song, Zhehui Chen, Huiting Zhang, Ying Jin, Mengqiu Li, Dingding Dong, Liying Sun, Zhijun Zhu, Yao Zhang, and Yanling Yang. Clinical features and cps1 variants in chinese patients with carbamoyl phosphate synthetase 1 deficiency. BMC Pediatrics, Aug 2024. URL: https://doi.org/10.1186/s12887-024-05005-5, doi:10.1186/s12887-024-05005-5. This article has 5 citations and is from a peer-reviewed journal.

2. (fernandez2015usingrecombinanthuman pages 71-77): CARMEN DÍEZ FERNÁNDEZ. USING RECOMBINANT HUMAN CARBAMOYL PHOSPHATE SYNTHETASE 1 (CPS1) FOR STUDYING THIS ENZYME'S FUNCTION, REGULATION, PATHOLOGY AND STRUCTURE. PhD thesis, Universitat Politecnica de Valencia, 2015. URL: https://doi.org/10.4995/thesis/10251/52855, doi:10.4995/thesis/10251/52855.

3. (fernandez2015usingrecombinanthuman pages 106-110): CARMEN DÍEZ FERNÁNDEZ. USING RECOMBINANT HUMAN CARBAMOYL PHOSPHATE SYNTHETASE 1 (CPS1) FOR STUDYING THIS ENZYME'S FUNCTION, REGULATION, PATHOLOGY AND STRUCTURE. PhD thesis, Universitat Politecnica de Valencia, 2015. URL: https://doi.org/10.4995/thesis/10251/52855, doi:10.4995/thesis/10251/52855.

4. (fernandez2015usingrecombinanthuman pages 85-89): CARMEN DÍEZ FERNÁNDEZ. USING RECOMBINANT HUMAN CARBAMOYL PHOSPHATE SYNTHETASE 1 (CPS1) FOR STUDYING THIS ENZYME'S FUNCTION, REGULATION, PATHOLOGY AND STRUCTURE. PhD thesis, Universitat Politecnica de Valencia, 2015. URL: https://doi.org/10.4995/thesis/10251/52855, doi:10.4995/thesis/10251/52855.

5. (pekkala2010understandingcarbamoyl‐phosphatesynthetase pages 1-2): Satu Pekkala, Ana I. Martínez, Belén Barcelona, Igor Yefimenko, Ulrich Finckh, Vicente Rubio, and Javier Cervera. Understanding carbamoyl‐phosphate synthetase i (cps1) deficiency by using expression studies and structure‐based analysis. Human Mutation, 31:801-808, Jul 2010. URL: https://doi.org/10.1002/humu.21272, doi:10.1002/humu.21272. This article has 50 citations and is from a domain leading peer-reviewed journal.

6. (fernandez2015usingrecombinanthuman pages 37-41): CARMEN DÍEZ FERNÁNDEZ. USING RECOMBINANT HUMAN CARBAMOYL PHOSPHATE SYNTHETASE 1 (CPS1) FOR STUDYING THIS ENZYME'S FUNCTION, REGULATION, PATHOLOGY AND STRUCTURE. PhD thesis, Universitat Politecnica de Valencia, 2015. URL: https://doi.org/10.4995/thesis/10251/52855, doi:10.4995/thesis/10251/52855.

7. (OpenTargets Search: -CPS1): Open Targets Query (-CPS1, 9 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

8. (haskins2021mitochondrialenzymesof pages 2-3): Nantaporn Haskins, Shivaprasad Bhuvanendran, Claudio Anselmi, Anna Gams, Tomas Kanholm, Kristen M. Kocher, Jonathan LoTempio, Kylie I. Krohmaly, Danielle Sohai, Nathaniel Stearrett, Erin Bonner, Mendel Tuchman, Hiroki Morizono, Jyoti K. Jaiswal, and Ljubica Caldovic. Mitochondrial enzymes of the urea cycle cluster at the inner mitochondrial membrane. Frontiers in Physiology, Jan 2021. URL: https://doi.org/10.3389/fphys.2020.542950, doi:10.3389/fphys.2020.542950. This article has 40 citations.

9. (haskins2021mitochondrialenzymesof pages 1-2): Nantaporn Haskins, Shivaprasad Bhuvanendran, Claudio Anselmi, Anna Gams, Tomas Kanholm, Kristen M. Kocher, Jonathan LoTempio, Kylie I. Krohmaly, Danielle Sohai, Nathaniel Stearrett, Erin Bonner, Mendel Tuchman, Hiroki Morizono, Jyoti K. Jaiswal, and Ljubica Caldovic. Mitochondrial enzymes of the urea cycle cluster at the inner mitochondrial membrane. Frontiers in Physiology, Jan 2021. URL: https://doi.org/10.3389/fphys.2020.542950, doi:10.3389/fphys.2020.542950. This article has 40 citations.

10. (fernandez2015usingrecombinanthuman pages 24-31): CARMEN DÍEZ FERNÁNDEZ. USING RECOMBINANT HUMAN CARBAMOYL PHOSPHATE SYNTHETASE 1 (CPS1) FOR STUDYING THIS ENZYME'S FUNCTION, REGULATION, PATHOLOGY AND STRUCTURE. PhD thesis, Universitat Politecnica de Valencia, 2015. URL: https://doi.org/10.4995/thesis/10251/52855, doi:10.4995/thesis/10251/52855.

11. (yao2020smallmoleculeinhibition pages 1-3): Shihua Yao, Tuong-Vi Nguyen, Alan Rolfe, Anant A. Agrawal, Jiyuan Ke, Shouyong Peng, Federico Colombo, Sean Yu, Patricia Bouchard, Jiayi Wu, Kuan-Chun Huang, Xingfeng Bao, Kiyoyuki Omoto, Anand Selvaraj, Lihua Yu, Stephanos Ioannidis, Frédéric H. Vaillancourt, Ping Zhu, Nicholas A. Larsen, and David M. Bolduc. Small molecule inhibition of cps1 activity through an allosteric pocket. Cell Chemical Biology, 27:259-268.e5, Mar 2020. URL: https://doi.org/10.1016/j.chembiol.2020.01.009, doi:10.1016/j.chembiol.2020.01.009. This article has 41 citations and is from a domain leading peer-reviewed journal.

12. (fernandez2015usingrecombinanthuman pages 41-44): CARMEN DÍEZ FERNÁNDEZ. USING RECOMBINANT HUMAN CARBAMOYL PHOSPHATE SYNTHETASE 1 (CPS1) FOR STUDYING THIS ENZYME'S FUNCTION, REGULATION, PATHOLOGY AND STRUCTURE. PhD thesis, Universitat Politecnica de Valencia, 2015. URL: https://doi.org/10.4995/thesis/10251/52855, doi:10.4995/thesis/10251/52855.

13. (nakagawa2009sirt5deacetylatescarbamoyl pages 3-4): Takashi Nakagawa, David J. Lomb, Marcia C. Haigis, and Leonard Guarente. Sirt5 deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell, 137:560-570, May 2009. URL: https://doi.org/10.1016/j.cell.2009.02.026, doi:10.1016/j.cell.2009.02.026. This article has 992 citations and is from a highest quality peer-reviewed journal.

14. (nakagawa2009sirt5deacetylatescarbamoyl pages 7-8): Takashi Nakagawa, David J. Lomb, Marcia C. Haigis, and Leonard Guarente. Sirt5 deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell, 137:560-570, May 2009. URL: https://doi.org/10.1016/j.cell.2009.02.026, doi:10.1016/j.cell.2009.02.026. This article has 992 citations and is from a highest quality peer-reviewed journal.

15. (nakagawa2009sirt5deacetylatescarbamoyl pages 6-7): Takashi Nakagawa, David J. Lomb, Marcia C. Haigis, and Leonard Guarente. Sirt5 deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell, 137:560-570, May 2009. URL: https://doi.org/10.1016/j.cell.2009.02.026, doi:10.1016/j.cell.2009.02.026. This article has 992 citations and is from a highest quality peer-reviewed journal.

16. (soria2022oglcnacylationenhancescps1 pages 4-4): Leandro R. Soria, Georgios Makris, Alfonso M. D’Alessio, Angela De Angelis, Iolanda Boffa, Veronica M. Pravata, Véronique Rüfenacht, Sergio Attanasio, Edoardo Nusco, Paola Arena, Andrew T. Ferenbach, Debora Paris, Paola Cuomo, Andrea Motta, Matthew Nitzahn, Gerald S. Lipshutz, Ainhoa Martínez-Pizarro, Eva Richard, Lourdes R. Desviat, Johannes Häberle, Daan M. F. van Aalten, and Nicola Brunetti-Pierri. O-glcnacylation enhances cps1 catalytic efficiency for ammonia and promotes ureagenesis. Nature Communications, Sep 2022. URL: https://doi.org/10.1038/s41467-022-32904-x, doi:10.1038/s41467-022-32904-x. This article has 23 citations and is from a highest quality peer-reviewed journal.

17. (soria2022oglcnacylationenhancescps1 pages 6-7): Leandro R. Soria, Georgios Makris, Alfonso M. D’Alessio, Angela De Angelis, Iolanda Boffa, Veronica M. Pravata, Véronique Rüfenacht, Sergio Attanasio, Edoardo Nusco, Paola Arena, Andrew T. Ferenbach, Debora Paris, Paola Cuomo, Andrea Motta, Matthew Nitzahn, Gerald S. Lipshutz, Ainhoa Martínez-Pizarro, Eva Richard, Lourdes R. Desviat, Johannes Häberle, Daan M. F. van Aalten, and Nicola Brunetti-Pierri. O-glcnacylation enhances cps1 catalytic efficiency for ammonia and promotes ureagenesis. Nature Communications, Sep 2022. URL: https://doi.org/10.1038/s41467-022-32904-x, doi:10.1038/s41467-022-32904-x. This article has 23 citations and is from a highest quality peer-reviewed journal.

18. (wu2022regulationofthe pages 1-2): Jing Wu, Jiayu Liu, Kalina Lapenta, Reina Desrouleaux, Min-Dian Li, and Xiaoyong Yang. Regulation of the urea cycle by cps1 o-glcnacylation in response to dietary restriction and aging. Journal of Molecular Cell Biology, Mar 2022. URL: https://doi.org/10.1093/jmcb/mjac016, doi:10.1093/jmcb/mjac016. This article has 17 citations and is from a peer-reviewed journal.

19. (wu2022regulationofthe pages 2-5): Jing Wu, Jiayu Liu, Kalina Lapenta, Reina Desrouleaux, Min-Dian Li, and Xiaoyong Yang. Regulation of the urea cycle by cps1 o-glcnacylation in response to dietary restriction and aging. Journal of Molecular Cell Biology, Mar 2022. URL: https://doi.org/10.1093/jmcb/mjac016, doi:10.1093/jmcb/mjac016. This article has 17 citations and is from a peer-reviewed journal.

20. (dong2024clinicalfeaturesand pages 1-2): Hui Dong, Tian Sang, Xue Ma, Jinqing Song, Zhehui Chen, Huiting Zhang, Ying Jin, Mengqiu Li, Dingding Dong, Liying Sun, Zhijun Zhu, Yao Zhang, and Yanling Yang. Clinical features and cps1 variants in chinese patients with carbamoyl phosphate synthetase 1 deficiency. BMC Pediatrics, Aug 2024. URL: https://doi.org/10.1186/s12887-024-05005-5, doi:10.1186/s12887-024-05005-5. This article has 5 citations and is from a peer-reviewed journal.

21. (dong2024clinicalfeaturesand pages 4-5): Hui Dong, Tian Sang, Xue Ma, Jinqing Song, Zhehui Chen, Huiting Zhang, Ying Jin, Mengqiu Li, Dingding Dong, Liying Sun, Zhijun Zhu, Yao Zhang, and Yanling Yang. Clinical features and cps1 variants in chinese patients with carbamoyl phosphate synthetase 1 deficiency. BMC Pediatrics, Aug 2024. URL: https://doi.org/10.1186/s12887-024-05005-5, doi:10.1186/s12887-024-05005-5. This article has 5 citations and is from a peer-reviewed journal.

22. (wang2023clinicalandgenetic pages 3-5): Shangyu Wang, Jinglin Chen, Xiaoqi Zhu, Tingting Huang, Haifeng Xu, Guohuan Ying, Hao Qian, Wenxin Lin, Yiehen Tung, Kaleem Ullah Khan, Hu Guo, Guo Zheng, Haiying Lu, and Gang Zhang. Clinical and genetic analysis of a case of late onset carbamoyl phosphate synthase i deficiency caused by cps1 mutation and literature review. BMC Medical Genomics, Jun 2023. URL: https://doi.org/10.1186/s12920-023-01569-w, doi:10.1186/s12920-023-01569-w. This article has 10 citations and is from a peer-reviewed journal.

23. (liu2011dnamethylationsuppresses pages 4-6): Hongyan Liu, Huijia Dong, Keith Robertson, and Chen Liu. Dna methylation suppresses expression of the urea cycle enzyme carbamoyl phosphate synthetase 1 (cps1) in human hepatocellular carcinoma. The American journal of pathology, 178 2:652-61, Feb 2011. URL: https://doi.org/10.1016/j.ajpath.2010.10.023, doi:10.1016/j.ajpath.2010.10.023. This article has 133 citations.

24. (hajaj2023fromtheinside pages 4-5): Emma Hajaj, Sabina Pozzi, and Ayelet Erez. From the inside out: exposing the roles of urea cycle enzymes in tumors and their micro and macro environments. Cold Spring Harbor perspectives in medicine, 14:a041538, Sep 2024. URL: https://doi.org/10.1101/cshperspect.a041538, doi:10.1101/cshperspect.a041538. This article has 12 citations and is from a peer-reviewed journal.

25. (yao2020smallmoleculeinhibition pages 8-8): Shihua Yao, Tuong-Vi Nguyen, Alan Rolfe, Anant A. Agrawal, Jiyuan Ke, Shouyong Peng, Federico Colombo, Sean Yu, Patricia Bouchard, Jiayi Wu, Kuan-Chun Huang, Xingfeng Bao, Kiyoyuki Omoto, Anand Selvaraj, Lihua Yu, Stephanos Ioannidis, Frédéric H. Vaillancourt, Ping Zhu, Nicholas A. Larsen, and David M. Bolduc. Small molecule inhibition of cps1 activity through an allosteric pocket. Cell Chemical Biology, 27:259-268.e5, Mar 2020. URL: https://doi.org/10.1016/j.chembiol.2020.01.009, doi:10.1016/j.chembiol.2020.01.009. This article has 41 citations and is from a domain leading peer-reviewed journal.

26. (yao2020smallmoleculeinhibition pages 14-15): Shihua Yao, Tuong-Vi Nguyen, Alan Rolfe, Anant A. Agrawal, Jiyuan Ke, Shouyong Peng, Federico Colombo, Sean Yu, Patricia Bouchard, Jiayi Wu, Kuan-Chun Huang, Xingfeng Bao, Kiyoyuki Omoto, Anand Selvaraj, Lihua Yu, Stephanos Ioannidis, Frédéric H. Vaillancourt, Ping Zhu, Nicholas A. Larsen, and David M. Bolduc. Small molecule inhibition of cps1 activity through an allosteric pocket. Cell Chemical Biology, 27:259-268.e5, Mar 2020. URL: https://doi.org/10.1016/j.chembiol.2020.01.009, doi:10.1016/j.chembiol.2020.01.009. This article has 41 citations and is from a domain leading peer-reviewed journal.

27. (yao2020smallmoleculeinhibition pages 5-7): Shihua Yao, Tuong-Vi Nguyen, Alan Rolfe, Anant A. Agrawal, Jiyuan Ke, Shouyong Peng, Federico Colombo, Sean Yu, Patricia Bouchard, Jiayi Wu, Kuan-Chun Huang, Xingfeng Bao, Kiyoyuki Omoto, Anand Selvaraj, Lihua Yu, Stephanos Ioannidis, Frédéric H. Vaillancourt, Ping Zhu, Nicholas A. Larsen, and David M. Bolduc. Small molecule inhibition of cps1 activity through an allosteric pocket. Cell Chemical Biology, 27:259-268.e5, Mar 2020. URL: https://doi.org/10.1016/j.chembiol.2020.01.009, doi:10.1016/j.chembiol.2020.01.009. This article has 41 citations and is from a domain leading peer-reviewed journal.

28. (fernandez2015usingrecombinanthuman pages 133-137): CARMEN DÍEZ FERNÁNDEZ. USING RECOMBINANT HUMAN CARBAMOYL PHOSPHATE SYNTHETASE 1 (CPS1) FOR STUDYING THIS ENZYME'S FUNCTION, REGULATION, PATHOLOGY AND STRUCTURE. PhD thesis, Universitat Politecnica de Valencia, 2015. URL: https://doi.org/10.4995/thesis/10251/52855, doi:10.4995/thesis/10251/52855.

29. (haskins2021mitochondrialenzymesof pages 11-13): Nantaporn Haskins, Shivaprasad Bhuvanendran, Claudio Anselmi, Anna Gams, Tomas Kanholm, Kristen M. Kocher, Jonathan LoTempio, Kylie I. Krohmaly, Danielle Sohai, Nathaniel Stearrett, Erin Bonner, Mendel Tuchman, Hiroki Morizono, Jyoti K. Jaiswal, and Ljubica Caldovic. Mitochondrial enzymes of the urea cycle cluster at the inner mitochondrial membrane. Frontiers in Physiology, Jan 2021. URL: https://doi.org/10.3389/fphys.2020.542950, doi:10.3389/fphys.2020.542950. This article has 40 citations.

30. (haskins2021mitochondrialenzymesof pages 13-14): Nantaporn Haskins, Shivaprasad Bhuvanendran, Claudio Anselmi, Anna Gams, Tomas Kanholm, Kristen M. Kocher, Jonathan LoTempio, Kylie I. Krohmaly, Danielle Sohai, Nathaniel Stearrett, Erin Bonner, Mendel Tuchman, Hiroki Morizono, Jyoti K. Jaiswal, and Ljubica Caldovic. Mitochondrial enzymes of the urea cycle cluster at the inner mitochondrial membrane. Frontiers in Physiology, Jan 2021. URL: https://doi.org/10.3389/fphys.2020.542950, doi:10.3389/fphys.2020.542950. This article has 40 citations.

31. (haskins2021mitochondrialenzymesof pages 5-7): Nantaporn Haskins, Shivaprasad Bhuvanendran, Claudio Anselmi, Anna Gams, Tomas Kanholm, Kristen M. Kocher, Jonathan LoTempio, Kylie I. Krohmaly, Danielle Sohai, Nathaniel Stearrett, Erin Bonner, Mendel Tuchman, Hiroki Morizono, Jyoti K. Jaiswal, and Ljubica Caldovic. Mitochondrial enzymes of the urea cycle cluster at the inner mitochondrial membrane. Frontiers in Physiology, Jan 2021. URL: https://doi.org/10.3389/fphys.2020.542950, doi:10.3389/fphys.2020.542950. This article has 40 citations.

32. (haskins2021mitochondrialenzymesof pages 7-10): Nantaporn Haskins, Shivaprasad Bhuvanendran, Claudio Anselmi, Anna Gams, Tomas Kanholm, Kristen M. Kocher, Jonathan LoTempio, Kylie I. Krohmaly, Danielle Sohai, Nathaniel Stearrett, Erin Bonner, Mendel Tuchman, Hiroki Morizono, Jyoti K. Jaiswal, and Ljubica Caldovic. Mitochondrial enzymes of the urea cycle cluster at the inner mitochondrial membrane. Frontiers in Physiology, Jan 2021. URL: https://doi.org/10.3389/fphys.2020.542950, doi:10.3389/fphys.2020.542950. This article has 40 citations.

33. (mitchell2009geneticvariationin pages 2-3): Sabrina Mitchell, Clint Ellingson, Thomas Coyne, Lynn Hall, Meaghan Neill, Natalie Christian, Catherine Higham, Steven F. Dobrowolski, Mendel Tuchman, and Marshall Summar. Genetic variation in the urea cycle: a model resource for investigating key candidate genes for common diseases. Human Mutation, 30:56-60, Jan 2009. URL: https://doi.org/10.1002/humu.20813, doi:10.1002/humu.20813. This article has 57 citations and is from a domain leading peer-reviewed journal.

34. (zhu2026ureacycledysregulation pages 5-7): Boying Zhu, Chaoyang Wang, Peng Liu, Zhifeng Qu, Ran Qi, Shengjiang Chen, and Huanzhang Niu. Urea cycle dysregulation and arginine pathways in the pathogenesis of nafld and nash (review). International Journal of Molecular Medicine, 58:1-21, Jun 2026. URL: https://doi.org/10.3892/ijmm.2026.5886, doi:10.3892/ijmm.2026.5886. This article has 0 citations and is from a peer-reviewed journal.

35. (nakagawa2009sirt5deacetylatescarbamoyl pages 1-2): Takashi Nakagawa, David J. Lomb, Marcia C. Haigis, and Leonard Guarente. Sirt5 deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell, 137:560-570, May 2009. URL: https://doi.org/10.1016/j.cell.2009.02.026, doi:10.1016/j.cell.2009.02.026. This article has 992 citations and is from a highest quality peer-reviewed journal.

36. (nakagawa2009sirt5deacetylatescarbamoyl pages 5-6): Takashi Nakagawa, David J. Lomb, Marcia C. Haigis, and Leonard Guarente. Sirt5 deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell, 137:560-570, May 2009. URL: https://doi.org/10.1016/j.cell.2009.02.026, doi:10.1016/j.cell.2009.02.026. This article has 992 citations and is from a highest quality peer-reviewed journal.

37. (soria2022oglcnacylationenhancescps1 pages 7-8): Leandro R. Soria, Georgios Makris, Alfonso M. D’Alessio, Angela De Angelis, Iolanda Boffa, Veronica M. Pravata, Véronique Rüfenacht, Sergio Attanasio, Edoardo Nusco, Paola Arena, Andrew T. Ferenbach, Debora Paris, Paola Cuomo, Andrea Motta, Matthew Nitzahn, Gerald S. Lipshutz, Ainhoa Martínez-Pizarro, Eva Richard, Lourdes R. Desviat, Johannes Häberle, Daan M. F. van Aalten, and Nicola Brunetti-Pierri. O-glcnacylation enhances cps1 catalytic efficiency for ammonia and promotes ureagenesis. Nature Communications, Sep 2022. URL: https://doi.org/10.1038/s41467-022-32904-x, doi:10.1038/s41467-022-32904-x. This article has 23 citations and is from a highest quality peer-reviewed journal.

38. (wu2022regulationofthe pages 5-6): Jing Wu, Jiayu Liu, Kalina Lapenta, Reina Desrouleaux, Min-Dian Li, and Xiaoyong Yang. Regulation of the urea cycle by cps1 o-glcnacylation in response to dietary restriction and aging. Journal of Molecular Cell Biology, Mar 2022. URL: https://doi.org/10.1093/jmcb/mjac016, doi:10.1093/jmcb/mjac016. This article has 17 citations and is from a peer-reviewed journal.

39. (wu2022regulationofthe pages 7-9): Jing Wu, Jiayu Liu, Kalina Lapenta, Reina Desrouleaux, Min-Dian Li, and Xiaoyong Yang. Regulation of the urea cycle by cps1 o-glcnacylation in response to dietary restriction and aging. Journal of Molecular Cell Biology, Mar 2022. URL: https://doi.org/10.1093/jmcb/mjac016, doi:10.1093/jmcb/mjac016. This article has 17 citations and is from a peer-reviewed journal.

40. (yao2020smallmoleculeinhibition pages 4-5): Shihua Yao, Tuong-Vi Nguyen, Alan Rolfe, Anant A. Agrawal, Jiyuan Ke, Shouyong Peng, Federico Colombo, Sean Yu, Patricia Bouchard, Jiayi Wu, Kuan-Chun Huang, Xingfeng Bao, Kiyoyuki Omoto, Anand Selvaraj, Lihua Yu, Stephanos Ioannidis, Frédéric H. Vaillancourt, Ping Zhu, Nicholas A. Larsen, and David M. Bolduc. Small molecule inhibition of cps1 activity through an allosteric pocket. Cell Chemical Biology, 27:259-268.e5, Mar 2020. URL: https://doi.org/10.1016/j.chembiol.2020.01.009, doi:10.1016/j.chembiol.2020.01.009. This article has 41 citations and is from a domain leading peer-reviewed journal.

Artifacts

• Edison artifact artifact-00

Citations

1. dong2024clinicalfeaturesand pages 5-6
2. dong2024clinicalfeaturesand pages 4-5
3. fernandez2015usingrecombinanthuman pages 41-44
4. fernandez2015usingrecombinanthuman pages 37-41
5. fernandez2015usingrecombinanthuman pages 24-31
6. yao2020smallmoleculeinhibition pages 5-7
7. haskins2021mitochondrialenzymesof pages 11-13
8. haskins2021mitochondrialenzymesof pages 13-14
9. haskins2021mitochondrialenzymesof pages 1-2
10. zhu2026ureacycledysregulation pages 5-7
11. hajaj2023fromtheinside pages 4-5
12. fernandez2015usingrecombinanthuman pages 133-137
13. wu2022regulationofthe pages 7-9
14. liu2011dnamethylationsuppresses pages 4-6
15. fernandez2015usingrecombinanthuman pages 71-77
16. fernandez2015usingrecombinanthuman pages 106-110
17. fernandez2015usingrecombinanthuman pages 85-89
18. haskins2021mitochondrialenzymesof pages 2-3
19. yao2020smallmoleculeinhibition pages 1-3
20. wu2022regulationofthe pages 1-2
21. wu2022regulationofthe pages 2-5
22. dong2024clinicalfeaturesand pages 1-2
23. wang2023clinicalandgenetic pages 3-5
24. yao2020smallmoleculeinhibition pages 8-8
25. yao2020smallmoleculeinhibition pages 14-15
26. haskins2021mitochondrialenzymesof pages 5-7
27. haskins2021mitochondrialenzymesof pages 7-10
28. mitchell2009geneticvariationin pages 2-3
29. wu2022regulationofthe pages 5-6
30. yao2020smallmoleculeinhibition pages 4-5
31. ammonia
32. https://doi.org/10.1186/s12887-024-05005-5,
33. https://doi.org/10.4995/thesis/10251/52855,
34. https://doi.org/10.1002/humu.21272,
35. https://doi.org/10.3389/fphys.2020.542950,
36. https://doi.org/10.1016/j.chembiol.2020.01.009,
37. https://doi.org/10.1016/j.cell.2009.02.026,
38. https://doi.org/10.1038/s41467-022-32904-x,
39. https://doi.org/10.1093/jmcb/mjac016,
40. https://doi.org/10.1186/s12920-023-01569-w,
41. https://doi.org/10.1016/j.ajpath.2010.10.023,
42. https://doi.org/10.1101/cshperspect.a041538,
43. https://doi.org/10.1002/humu.20813,
44. https://doi.org/10.3892/ijmm.2026.5886,